Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at UBS Global Healthcare Conference Transcript

May 21, 2019 / 01:30PM GMT
Release Date Price: R$15.97
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

(technical difficulty)

to UBS Global Healthcare conference Day 2. My name is Navin Jacob. I'm the senior analyst for global pharma and for smid-cap biotech. I'm happy to have here with me, Christi Shaw, SVP and President of Lilly Biosciences. Thank you for joining us, Christi.

Christi Shaw
Eli Lilly and Company - Senior VP & President of Lilly Bio-Medicines

Absolutely. Hello everyone.

Questions & Answers

Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

So Christi, you're responsible for a portfolio that includes pain and inflammation. Those spaces, particularly inflammation, like diabetes, is a space that is highly rebated. The administration has a proposal to change the rebate rule and -- or has a rebate rule proposed. Wondering how you think about the potential

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot